WO1995032739A1 - Cyclodextrin cellular delivery system for oligonucleotides - Google Patents
Cyclodextrin cellular delivery system for oligonucleotides Download PDFInfo
- Publication number
- WO1995032739A1 WO1995032739A1 PCT/US1995/006916 US9506916W WO9532739A1 WO 1995032739 A1 WO1995032739 A1 WO 1995032739A1 US 9506916 W US9506916 W US 9506916W WO 9532739 A1 WO9532739 A1 WO 9532739A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- oligonucleotide
- oligonucleotides
- composition
- adamantane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- This invention relates to antisense therapy. More particularly, this invention relates to compositions and methods for enhancing the cellular uptake of antisense oligonucleotides.
- antisense oligonucleotides are single-stranded oligonucleotides which bind to a target nucleic acid molecules according to the Watson-Crick or Hoogsteen rule of base pairing, and in doing so, disrupt the function of the target by one of several mechanisms: by preventing the binding of factors required for normal transcription, splicing, or translation; by triggering the enzymatic destruction of RNA by RNase H, or by destroying the target via reactive groups attached directly to the antisense oligonucleotide.
- antisense molecules In order for antisense molecules to have therapeutic value, they must have the ability to enter a cell and contact target endogenous nucleic acids. Furthermore, they must be able to withstand the rigors of the highly nucleolytic environment of the cell .
- oligonucleotides with phosphorothioate or methylphosphonate internucleotide linkages have been found to bind to, and to be taken up by cells more readily than phosphodiester-linked oligonucleotides (Zhao et a. (1993) Antisense Res . Dev. 3:53-56) .
- Oligonucleotide uptake is saturable, sequence-independent, and temperature and energy dependent. While there is some evidence to suggest that such uptake may occur through a 80,000 dalton membrane protein ( oke et al. (1989) Proc . Natl . Acad. Sci . (USA) 86:3474; Yakubov et al. (1989) Proc . Natl . Acad. Sci . (USA) 86:6454), the gene for this protein has not yet been cloned or characterized.
- One study suggests internalization of the oligonucleotide is by a caveolar, protocytotic mechanism rather than by endocytosis (Zamecnick (1994) Proc. Natl . Acad. Sci . (USA) 91:3156) . Whether oligonucleotides are internalized via a receptor-mediated endocytotic pathway, a pinocytic mechanism, or a combination of both remains poorly understood.
- WO 9323570 discloses an oligonucleotide with improved cellular uptake having at least one nucleotide residue covalently linked at its 2' position with various molecules including an amino acid, polypeptide, protein, sugar, sugar phosphate, neurotransmitter, hormone, cyclodextrin, starch, steroid, or vitamin.
- Enhanced cellular uptake of biotinylated oligonucleotide in the presence of avidin has also been demonstrated (Partridge et al. (1991) FEBS Lett . 288:30-32) .
- phosphodiester-linked oligodeoxy-nucleotides have been introduced into cells by the pore-forming agent streptolysin O (Barry et al. (1993) Biotechniques 15:1016-1018) , and a liposomal preparation including cationic lipid has been shown to enhance the cellular uptake of antisense molecules targeted to a portion of the human intercellular adhesion molecule (Bennett et al. (1992) Mol . Pharmacol . 41:1023-1033) .
- Phosphodiester-linked oligonucleotides bearing a 5' -cholesteryl modification show increased cellular uptake and biological effects (Krieg et al. (1993) Proc . Natl .
- Antibody- targeted liposomes have also been used to enhance the cellular uptake of oligonucleotides targeted to HLA class I molecules expressed by HIV-infected cells (Zelphati et al . (1993) Antisense Res . Dev. 3:323-338) .
- compositions and methods will also be useful for increasing the general solubility of oligonucleotides.
- the oligonucleotide is noncovalently associated directly to the cyclodextrin, which preferably is a beta ( ⁇ ) - cyclodextrin, a gamma ( ⁇ ) -2-cyclodextrin, a methyl substituted cyclodextrin, or a derivative thereof.
- the cyclodextrin which preferably is a beta ( ⁇ ) - cyclodextrin, a gamma ( ⁇ ) -2-cyclodextrin, a methyl substituted cyclodextrin, or a derivative thereof.
- Preferred derivatives include 2-hydroxypropyl- ⁇ - cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin polysulfate, trimethyl ⁇ -cyclodextrin, and ⁇ - cyclodextrin polysulfate, and methyl substituted cyclodextrins.
- the oligonucleotide to which the cyclodextrin is complexed contains at least one deoxyribonucleotide, one ribonucleotide, or both deoxyribonucleotides and ribonucleotides (i.e., a chimeric oligonucleotide) .
- the oligonucleotide is interconnected with phosphodiester internucleotide linkages in some embodiments, while in others, the oligonucleotide is modified.
- modified oligonucleotide is used herein as an oligonucleotide in which at least two of its nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester between the 5' end of one nucleotide and the 3' end of another nucleotide in which the 5' nucleotide phosphate has been replaced with any number of chemical groups.
- Preferable synthetic linkages include alkylphosphonates, phosphate esters, alkylphosphonates, phosphorothioates, phosphorodithioates, 2-0-methyl carbonates, alkylphosphonothioates, phosphoramidates, carbamates, phosphate triesters, acetamidate, and carboxymethyl esters.
- the oligonucleotide comprises at least one phosphorothioate and/or one alkylphosphonate linkage.
- modified oligonucleotide also encompasses oligonucleotides with a modified base and/or sugar.
- a 3', 5' -substituted oligonucleotide is a modified oligonucleotide having a sugar which, at both its 3' and 5' positions is attached to a chemical group other than a hydroxyl group (at its 3' position) and other than a phosphate group (at its 5' position) .
- a modified oligonucleotide may also be a capped species.
- unoxidized or partially oxidized oligonucleotides having a substitution in one nonbridging oxygen per nucleotide in the molecule are also considered to be modified oligonucleotides.
- modified oligonucleotides are oligonucleotides having nuclease resistance-conferring bulky substituents at their 3' and/or 5' end(s) and/or various other structural modifications not found in vivo without human intervention are also considered herein as modified.
- the oligonucleotide of the composition of the invention is covalently bonded to adamantane which is noncovalently associated with the cyclodextrin.
- the covalent association is between the 3'- hydroxyl or the 5' -amino of the oligonucleotide and the adamantane.
- the adamantane is covalently associated with the 2'- hydroxyl of the ribonucleotide.
- This invention also provides a pharmaceutical formulation including the cyclodextrin-complexed oligonucleotide composition, preferably in a physiologically acceptable carrier.
- a pharmaceutical formulation including the cyclodextrin-complexed oligonucleotide composition, preferably in a physiologically acceptable carrier.
- Such a formulation is useful in a method of increasing the cellular uptake, and thus, of enhancing the intracellular concentration, of an exogenous oligonucleotide.
- the formulation is also used in a method of treating a cell, for example, for viral infection, or to prevent a viral infection.
- Also provided by this invention are methods of increasing the in vivo availability of an oligonucleotide by complexing it to a cyclodextrin.
- compositions which contain the oligonucleotide composition described above. These formulations are used in another aspect of the invention, namely, methods of increasing the cellular uptake and intracellular concentration of an exogenous oligonucleotide. In these methods, a cell is treated with the pharmaceutical formulation.
- a method of treating a cell for viral infection, or for the prevention of viral infection is provided.
- a cell is contacted with a pharmaceutical formulation containing an oligonucleotide having a nucleotide sequence complementary to a portion of the nucleic acid of a virus.
- the invention provides a useful composition for treating inadvertently infected cell culture lines. Contamination of cell lines with mycoplasma or viruses can be eliminated by using the compositions according to the invention.
- the invention also provides methods of increasing the solubility of an oligonucleotide in vivo, including the step of noncovalently complexing a cyclodextrin to an oligonucleotide.
- the oligonucleotide is covalently complexed with adamantane, and adamantane is noncovalently complexed to the cyclodextrin.
- FIG. 1A is a schematic representation of 2- hydroxypropyl- ⁇ -cyclodextrin (C 42 H 70 O 35 ) ;
- FIG. IB is a schematic representation of ⁇ -cyclodextrin (C 48 H 80 O 40 ) ;
- FIG. 2 is a flow cytometry data output record showing the fluorescent intensity of cell cultures treated with (A) no oligonucleotides; (B) PS oligonucleotide; (C) cyclodextrin-complexed PS oligonucleotide at 4°C over night; or (D) cyclodextrin-complexed PS oligonucleotide at 25°C for 1 hour;
- FIG. 3A is a photograph of a fluorescent micrograph showing cells treated with FITC-linked 20mer PS-oligonucleotide
- FIG. 3B is a photograph of a fluorescent micrograph showing cells with FITC-linked 20mer complexed with cyclodextrin;
- FIG. 3C is a photograph of a fluorescent micrograph showing cells treated with FITC-linked 42mer PS-oligonucleotide
- FIG. 3D is a photograph of a fluorescent micrograph showing cells with FITC-linked 42mer complexed with cyclodextrin;
- FIG. 4 is an autoradiograph of an SDS gel of cells extracted at various times after treatment with 32 P-labelled (A) uncomplexed or (B) cyclodextrin-complexed PO- and PS- oligonucleotides;
- FIG. 5 is an autoradiograph of an SDS gel comparing the relative mobilities of 32 P-labelled uncomplexed and cyclodextrin-complexed PO- and PS- oligonucleotides.
- FIG. 6 is a graphic representation of the fluorescent intensity of cell cultures treated with FITC-labelled uncomplexed, cyclodextrin- complexed, and cyclodextrin-adamantane complexed PS- oligonucleotides.
- FIG. 7 is a schematic representation of the preparation of adamantane-linked cyclodextrin
- FIG. 8 is a schematic representation of fluorescein phosphoramidite
- FIG. 9A is a schematic representation of a phosphodiester linked oligonucleotide covalently linked to adamantane
- FIG. 9B is a schematic representation of a PS-oligonucleotide covalently linked to adamantane
- FIG. 9C is a schematic representation of a FITC-conjugated PS-oligonucleotide covalently linked to adamantane.
- compositions which enhance the uptake of oligonucleotides into cells, thereby increasing the efficacy of the treatment and reducing the dose required.
- the compositions include an oligonucleotide complexed with a cyclodextrin or other polysaccharide.
- Cyclodextrins also known as cycloamyloses, are a group of cyclic polysaccharides consisting of six to eight naturally occurring D(+)- glucopyranose units in c.-(l,4) linkage. They are classified by the number of the glucose units they contain: alpha ( ⁇ ) -cyclodextrin has six glucose units; beta ( ⁇ ) -cyclodextrin has seven, and gamma ( ⁇ ) -cyclodextrin has eight (Brewster et al. (1989) J. Parenteral Sci. Technol. 43:231-240) .
- FIGS. 1A-1B show representative cyclodextrins of these classes.
- Cyclodextrins as a group are cone-shaped molecules have a slightly apolar internal cavity which can accommodate the inclusion of various other molecules. Their peripheral structure contains a large number of hydroxyl groups which provide water solubility. Some cyclodextrins and various substituted derivatives thereof, such as hydroxypropyl-, hydroxyethyl-, methyl-, or sulfate-substituted cyclodextrins, have the ability to enhance the solubility and availability of a variety of pharmacological agents.
- HPCD 2- hydroxypropyl ⁇ -cyclodextrin
- hydrophobic protein containing drugs such as insulin (Merkus et al. (1991) Pharmaceut. Res. 8:588-592), bovine growth hormone (Simpkins et al. (1991) J. Parenteral Sci . Technol . 45:266-269), and methyltestosterone
- ethylated- ⁇ -cyclodextrin has been used as slow-release type carriers for hydrophilic drugs such as diltiazem (Horiuchi et al. (199) J. Pharmaceut. Sci. 79:128-132) .
- cyclodextrins have unique biological features.
- cyclodextrin sulfates have anti-inflammatory, antilipemic, and antiviral activity, and have been found to inhibit replication of HIV by either prevention of viral absorption or budding (Pitha et al. (1991) J. Pharmaceutic. Res. 8:1151-1154; Anand et al. (199) Antiviral Chem. Chemother. 1:41-46) ; Moriya et al . (1991) J. Med. Chem. 34:2301-2304; Weiner et al. (1992) Pathobiol. 60:206-212).
- cyclodextrin sulfates have protective effects on the gentamicin-induced nephrotoxicity (Uekama et al. (1993) J. Pharm. Pharmacol . 45:745-747) and on hemolysis of erythrocytes (Weisz et al. (1993) Biochem . Pharmacol . 45:1011-1016) .
- cyclodextrins are biocompatible polymers composed of naturally occurring D-glucose subunits, their therapeutic application has been regarded are relatively safe. Indeed, in vivo administration of cyclodextrin concentrations of 5 to 10% has been generally used to enhance adsorption of drugs in animal studies, and no ' significant cytotoxic effects have been reported. (Gerloczy et al. (1994) J. Pharmaceut . Sci . 83:193-196) .
- cyclodextrins can be easily absorbed through nasal (Merkus et al. (1991) Pharm. Res . 8:588-592; Shao et al. (1992) Pharm. Res . 9:1157-1163) , intestinal (Nakanishi et al . (1992) Chem. Pharm. Bull . 40:1252-1256), corneal (Jansen et al . (1990) Lens Eye Tox. Res . 7:459-468) , rectal epithelium (Arima et al. (1992) J “ . Pharm. Soc . Japan 112:65-72), and by transdermal injection (Yoshida et al. (1990) Chem . Pharm . Bull . 38:176-179) .
- cyclodextrins have also been found to eliminate some of the undesirable side- effects of the drugs to which they have been complexed.
- 2-hydroxypropyl- ⁇ -cyclodextrin can suppress the immune reaction to a corneal graft (Arima et al . ( 1992 ) J. Pharmaceut.
- Cyclodextrins can be prepared by methods known in the art (see. e.g., Moriya et al. (1993) J. Med. Chem. 36:1674-1677) and are commercially available.
- oligonucleotides to which the cyclodextrin is complexed are composed of deoxyribonucleotides, ribonucleotides, or a combination of both, with the 5' end of one nucleotide and the 3' end of another nucleotide being covalently linked. These oligonucleotides are at least 6 nucleotides in length, but are preferably 10 to 50 nucleotides long, with 15 to 25mers being the most common. Oligonucleotides can be prepared by the art recognized methods such as phosphoramidate or H-phosphonate chemistry which can be carried out manually or by an automated synthesizer as described by Brown in A Brief History of Oligonucleotide Synthesis . Protocols for Oligonucleotides and Analogs, Methods in Molecular Biology (1994) 20:1-8) .
- the oligonucleotides of the composition may also be modified in a number of ways without compromising their ability to hybridize to the target nucleic acid and to complex with adamantane and/or cyclodextrin.
- the oligonucleotides may contains other than phosphodiester internucleotide linkages between the 5' end of one nucleotide and the 3' end of another nucleotide in which the 5' nucleotide phosphate has been replaced with any number of chemical groups.
- Oligonucleotides with these linkages can be prepared according to known methods (see, e.g., Sonveaux "Protecting Groups in Oligonucleotides Synthesis” in Agrawal (1994) Methods in Molecular Biology 26:1-72; Uhlmann et al. (1990) Chem. Rev. 90:543-583).
- modifications include those which are internal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the viral genome.
- cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the viral genome.
- modified oligonucleotides include oligonucleotides with a modified base and/or sugar such as arabinose instead of ribose, or a 3' , 5'- substituted oligonucleotide having a sugar which, at both its 3' and 5' positions is attached to a chemical group other than a hydroxyl group (at its 3' position) and other than a phosphate group (at its 5' position).
- Other modified oligonucleotides are capped with a nuclease resistance-conferring bulky substituent at their 3' and/or 5' end(s) , or have a substitution in one nonbridging oxygen per nucleotide.
- Such modifications can be at some or all of the internucleoside linkages, as well as at either or both ends of the oligonucleotide and/or in the interior of the molecule.
- Oligonucleotides which are self-stabilized are also considered to be modified oligonucleotides useful in the methods of the invention (Tang et al. (1993) Nucleic Acids Res . 20:2729-2735) . These oligonucleotides comprise two regions: a target hybridizing region; and a self-complementary region having an oligonucleotide sequence complementary to a nucleic acid sequence that is within the self- stabilized oligonucleotide.
- the oligonucleotides complexed to the cyclodextrin can have any nucleotide sequence desired and are able to hybridize to RNA or DNA under normal physiological conditions existing within a cell harboring the target nucleic acid. Such conditions include pH, temperature, and ionic conditions.
- nucleotides can be covalently linked using art-recognized techniques such as phosphoramidate, H-phosphonate chemistry, or methylphosphoramidate chemistry (see, e.g., Uhlmann et al. (1990) Chem . Rev. 90:543-584; Agrawal et al. (1987) Tetrahedron. Lett. 28 : (31) :3539-3542) ; Caruthers et al . (1987) Meth. Enzymol. 154:287-313; U.S. Patent 5,149,798) . Oligomeric phosphorothioate analogs can be prepared using methods well known in the field such as methoxyphosphoramidite (see, e.g. , Agrawal (1988)
- An oligonucleotide can be noncovalently complexed to a cyclodextrin by mixing them together in an aqueous solution such as a cellular growth medium or various buffers.
- an oligonucleotide can be covalently linked to an adamantane molecule which is then noncovalently linked to the cyclodextrin.
- Adamantane enters into the cavity of a cyclodextrin and forms a stable, noncovalent complex with it (Brinker et al . (1993) Angew. Chem., Int. Ed. Engl. 32:1344-1345, Ueno et al. (1993) J. Am. Chem. Soc. 115:12575-12576) .
- Linkage of the adamantane molecule can be accomplished at the 3'-hydroxyl or 5' amino terminus of the oligonucleotide having a (or both) deoxyribonucleotide terminal residue (s) termini.
- adamantane can be covalently complexed with the 2'-hydroxyl of a ribonucleotide residue. This can be accomplished with a linker phosphoramidite or H-phosphonate as the final coupling step in machine-aided assembly of an oligonucleotide, as has been used for the attachment of single reporter groups to a synthetic oligonucleotide (see, e.g., Agrawal et al. (1986) Nucleic Acids Res . 14:6229-6245;
- Covalent linkage of adamantane to the oligonucleotide can also be accomplished with the aid of an amino linker as described by Misiura et al. (J. Nucleic Acids Res . (1990) 18:4345-4353).
- the adamantane-linked oligonucleotide is then noncovalently associated with the cyclodextrin by mixing the two in an aqueous medium or buffer (see, e.g., Simpkins et al. (1991) J. Parental Sci . & Technol . 45:266) .
- the oligonucleotide composition or therapeutic formulation including the composition is useful in methods of increasing the cellular uptake and enhancing the intracellular concentration of an exogenous oligonucleotide, in methods of increasing the solubility of an oligonucleotide in vivo, and in methods of treating a cell, for example, for viral infection, or to prevent a viral infection.
- cyclodextrin-complexed oligonucleotides are taken up by cells was confirmed as follows. Fluorescein (FITC) -conjugated phosphorothioate (PS) oligonucleotides were complexed with cyclodextrin either at 4°C, overnight or at 25°C. Fluorescein (FITC) -conjugated phosphorothioate (PS) oligonucleotides were complexed with cyclodextrin either at 4°C, overnight or at 25°C for 1 hour. A cultured T cell leukemia cell line (CEM) was then contacted with the treated oligonucleotides. The fluorescent intensity of the CEM cells was measured by computer-analyzed flow cytometry.
- CEM T cell leukemia cell line
- FIG. 2 the fluorescent intensity is greatly increased when the oligonucleotide is complexed with cyclodextrin, indicating that complexation greatly increases cellular uptake.
- oligonucleotide affects the ability of the cyclodextrin to affect cellular uptake
- 20mer and 42mer FITC-conjugated PS-oligonucleotides were contacted with cyclodextrin at 25°C for 1 hour and then were added to CEM cells. The cells were examined under a fluorescent microscope.
- both the 20mer and the 42mer oligonucleotides which were complexed with cyclodextrin were taken up by the cells. Furthermore, more fluorescent cells were detected after treatment with oligonucleotides complexed with cyclodextrin than after treatment with uncomplexed oligonucleotides. This indicates that oligonucleotide uptake is enhanced by complexing with cyclodextrin.
- cyclodextrin-complexed 32 P-labelled PS- and PO-oligonucleotides administered to cell cultures were examined at different times after administration.
- the oligonucleotides were extracted from the cells and analyzed by electrophoresis and autoradiography.
- FITC oligonucleotide uptake into cells increased gradually during the time course studied. In the presence of cyclodextrin, the increase is much more dramatic, with the increase being the greatest with adamantane-linked oligonucleotides (oligonucleotide-A) .
- oligonucleotide-A adamantane-linked oligonucleotides
- the cycloxdetrin-associated or adamantane-linked, cyclodextrin-associated oligonucleotide is mixed with a physiologically acceptable carrier and then injected intravenously, intramuscularly, intraperitoneally, or by intranasal (Merkus et al. (1991) Pharmaceut. Res. 8:588-592; Shao et al . (1992) Pharmaceut. Res.
- Cyclodextrins can also be easily absorbed through intestinal (Nakanishi et al. (1992) Chem. Pharm. Bull. 40:1252-1256), corneal (Jansen et al. (1990) Lens Eye Toxicity Res. 7:459-468), and rectal (Arima et al. (1992) J. Pharmaceut. Soc. Japan 112:65-72) epithelium, and by transdermal injection (Yoshida et al. (1990) Chem. Pharmaceut. Bull. 38:176-179) .
- Effective dosages of the oligonucleotide and modes of its administration in the treatment of the particular disorder for which the oligonucleotide is being administered can be determined by routine experimentation.
- the pharmaceutical forms suitable for injectable or other use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile. It must be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents.
- Prolonged absorption of the injectable therapeutic agents can be brought about by the use of the compositions of agents delaying absorption.
- PO- and PS-oligonucleotides were synthesized on an automated synthesizer (Millipore 8700, Millipore Corp., Bedford, MA) using phosphoramidate chemistry (see Agrawal et al. (1989) Proc. Natl. Acad. Sci. (USA) 86:7790-7794; McBride et al. (1983) Tetrahedron Lett . 24:245) .
- oxidation reagents used in the syntheses were standard solution of iodine, for phosphodiester linkages, and 3 H-1, 2-benzodithiole-3-one-l, 1- dioxide as a solution of 1 g in 100 ml of acetonitrile, for phosphorothioate linkages formation.
- Methylphosphonates were prepared according to the method of Beaucage, "Oligonucleotide Synthesis: Phosphramidite Approach" in Protocols for Oligonucleotides and Analogs, Mehtods in Molecular Biology (1994) 20 :33-62) .
- Oligonucleotide concentrations were determined by absorbance at 260 nm, taking into account the molar extinction coefficient of the nucleotides present in each sequence (Ausubel et al . (eds . ) (1987) Current Protocols in Molecular Biology
- Fluorescein (FITC) was conjugated to the oligonucleotides through the 5'-hydroxyl using a fluorescein amidite (Clontech Laboratories, Inc., Palo Alto, CA) according to the method of Schubert (Nucleic Acids Res . (1990) 18:3427) . All oligonucleotides were deprotected by treatment with concentrated ammonia at 55°C for 12 hours. The oligonucleotides were purified by polyacrylamide gel electrophoresis (PAGE) , desalted by Sep-Pak C18 cartridges (Waters, Milliford, MA) and lyophilized to dryness prior to use.
- PAGE polyacrylamide gel electrophoresis
- 2-hydroxypropyl- ⁇ -cyclodextrin was prepared according to the method of Pitha et al. (Int. J. Pharm. (1986) 29:73-82) or obtained commercially from, e.g., Sigma Chemical Co., St. Louis, MO) .
- Other cyclodextrins such as ⁇ ( 36 H 6 o° 3 o) cyclodextrin and ⁇ - (C 48 H 80 O 40 ) cyclodextrin are also commercially available (from, e.g., Sigma Chemical Co., St.
- Oligonucleotides were 5' end labelled by incubating 200 ng oligonucleotide (PO or PS) with 2 ⁇ l polynucleotide kinase (Pharmacia, Piscataway, NJ) , and 2 ⁇ l of ( ⁇ - 32 P)ATP (Amersham LIFE Science, Arlington Heights, IL) in a final volume of 20 ⁇ l at 37°C for 1 hour.
- the mixture was passed over a Sephadex G-25 column (5 Prime-3 Prime, Boulder, CO) to separate the 32 P-labelled oligonucleotide from the unlabelled oligonucleotide.
- N-adamantoyl-3- aminopropyl solketal (compound 4) . More specifically, 5.0 g (26.42 mmole) of compound 3 was dissolved in dry dichloromethane (50 ml) under inert atmosphere of N 2 . To a solution was added dry triethylamine (4.2 ml, 3.04 g, 30.0 mmole) via syringe, following by dropwise addition of a solution of adamantanecarbonyl chloride (5.2 g, 260 mmole) in 10 ml dry dichloromethane. The solution was left to stir at room temperature for 1 hour and then concentrated.
- adamantanecarbonyl chloride 5.2 g, 260 mmole
- compound 5 (1-0- (4,4'- dimethoxytrityl) -3-0- (N-adamantoyl-3-aminopropyl) glycerol) , 8.56 g, (24.35 mmole) compound 4 was dissolved in a mixture of THF (48.7 ml) and 1 M aqueous HCl (48.7 ml) . The solution was stirred at room temperature for 30 minutes. 50 ml absolute ethanol (50 ml) was then added. The solution was concentrated, the residue was redissolved in 50 ml absolute ethanol, and the solution concentrated again.
- Compound 5 was further attached to long chain alkylamidopropanoic acid-controlled pore glass (CPG) beads, since the carboxyl moiety could be esterified with the free hydroxyl group of compound 5 in the presence of l-(3- dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, using standard procedures (Damha et al. (1990) Nucleic Acids Res . 8:3813-3821) to give compound 6. Loading was 22.1 ⁇ mole/g CPG.
- CPG long chain alkylamidopropanoic acid-controlled pore glass
- FIG. 9A the adamantane associated PS-oligonucleotide (SEQ ID NO:l) (FIG. 9B) , and the adamantane associated, FITC-conjugated PS-oligonucleotide (FIG. 9C) were cleaved off the CPG and deprotected with concentrated ammonia at room temperature for 15 hrs and then for 6 additional hours at 55°C.
- the 5'-ODMT protected oligonucleotides were purified on a preparative C-18 reverse phase column by elution with linear gradient of solvent A (0.1 M ammonium acetate) and solvent B (20% 0.1 M ammonium acetate + 80% of acetonitrile) .
- CEM a human T cell leukemia cell line (Foley et al. (1965) Cancer 4:522) , and H9, a human T- cell lymphoma cell line (American Type Culture Collection, Rockville, MD, ATCC No. HTB 176) were used in these studies. They were cultured in RPMI medium (JRH Biosciences, Lenexa, KS) supplemented with 10% heat inactivated (56°C for 30 min.) fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin solution (JRH Biosciences, Lenexa, KS) at 37°C in a 5% C0 2 - 95% 0 2 humidified air incubator.
- RPMI medium JRH Biosciences, Lenexa, KS
- H9 a human T- cell lymphoma cell line
- CEM cells were grown to subconfluency before experiment and resuspended in RPMI medium containing 20% fetal calf serum (FCS) (also contains penicillin streptomycin solution, glutamine as described before) .
- FCS fetal calf serum
- 1 ⁇ g FITC oligonucleotide that had been complexed with 10% HPCD or complexed (as control) (in 75 ⁇ l of plain RPMI media) were added to 5 x 10 s CEM cells in 75 ⁇ l of RPMI media containing 20% FCS.
- the final mixture contains 1 ⁇ g of FITC oligonucleotide, 5% HPCD, 5 x 10 5 CEM cells in 150 ⁇ l of RPMI media containing 10% FCS.
- the cells were cultured at 37°C for 4 hours and washed with Hank's balanced salt solution (HBSS) supplemented with 1% BSA, 1% sodium azide.
- HBSS Hank's balanced salt solution
- the fluorescence of CEM cells were then analyzed by flow cytometry (FACScan, Beckman- Dickson, Mountain View, CA; or Epics XL, Coulter, Hialeah, FL) , and analyzed with Lysis II software (when using FACScan) or Epics XL software, version 1.5 (when using Epics XL) (Zhao et al. (1993) Antisense Res . & Dev. 3:55) .
- CEM cells were grown to subconfluency before the experiment and resuspended in RPMI medium with 20% fetal calf serum (FCS) .
- FCS fetal calf serum
- the complex mixture in a volume of 175 ⁇ l plain RPMI medium
- 10 s CEM cells in 175 ⁇ l of RPMI medium containing 20% FCS.
- the final mixture contained 7 ⁇ g unlabeled oligonucleotide, about 80 ng of 32 P labelled oligonucleotide (the recovery efficiency of the Sephadex column is 80%) , 5% HPCD in 350 ⁇ l of RPMI medium containing 10 % FCS) .
- the treated cells were then cultured at 37°C.
- both 32 P-labelled (Amersham, Arlington Heights, IL) PO- and PS-oligonucleotides were purified through a spin column packed with Sephadex, mixed with 5% cyclodextrin in plain RPMI medium at 25°C for 1 hour, and then analyzed by electrophoresis on nondenaturing 15% polyacrylamide gels which were exposed for autoradiography (FIG. 5) .
- Fluorescently labelled PS-oligonucleotide, or fluorescently labelled, covalently-linked adamantane/PS-oligonucleotide were mixed with 1.25% HPCD in plain RMPI medium at 4°C for overnight complexing.
- 8 ⁇ g FITC oligonucleotides that had been complexed with 1.23% HPCD (as described above) or uncomplexed were added to 8 x 10 5 H9 cells in a final volume of 1.2 ml RMPI containing 10% fetal bovine serum. The cells were set to culture at 37°C.
- MOLECULE TYPE DNA (genomic)
- HYPOTHETICAL NO
- HYPOTHETICAL NO
- ANTI-SENSE YES
- SEQUENCE DESCRIPTION SEQ ID NO:1:
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK95922923T DK0762898T3 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin system for delivery of oligonucleotides to cells |
AU27643/95A AU2764395A (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
JP8501182A JPH10501237A (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cell delivery system for oligonucleotides |
DE69513395T DE69513395T2 (en) | 1994-06-01 | 1995-06-01 | CELLULAR DELIVERY SYSTEM WITH CYCLODEXTRIN, FOR OLIGONUCLEOTIDES |
EP95922923A EP0762898B1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
GR20000400052T GR3032355T3 (en) | 1994-06-01 | 2000-01-13 | Cyclodextrin cellular delivery system for oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25207294A | 1994-06-01 | 1994-06-01 | |
US08/252,072 | 1994-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995032739A1 true WO1995032739A1 (en) | 1995-12-07 |
Family
ID=22954476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/006916 WO1995032739A1 (en) | 1994-06-01 | 1995-06-01 | Cyclodextrin cellular delivery system for oligonucleotides |
Country Status (12)
Country | Link |
---|---|
US (3) | US5691316A (en) |
EP (1) | EP0762898B1 (en) |
JP (1) | JPH10501237A (en) |
CN (1) | CN1158088A (en) |
AT (1) | ATE186647T1 (en) |
AU (1) | AU2764395A (en) |
CA (1) | CA2191777A1 (en) |
DE (1) | DE69513395T2 (en) |
DK (1) | DK0762898T3 (en) |
ES (1) | ES2139904T3 (en) |
GR (1) | GR3032355T3 (en) |
WO (1) | WO1995032739A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010005A2 (en) * | 1995-09-12 | 1997-03-20 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
US7807198B2 (en) | 2000-12-19 | 2010-10-05 | California Institute Of Technology | Compositions containing inclusion complexes |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8357377B2 (en) | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US9260711B2 (en) | 2012-09-13 | 2016-02-16 | Ge Healthcare Uk Limited | Solid matrix for one step nucleic acid amplification |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030099959A1 (en) * | 1995-04-12 | 2003-05-29 | Kandimalla Ekambar R. | Cooperative oligonucleotides |
WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US6716589B2 (en) | 2000-11-20 | 2004-04-06 | Alphabeta Ab | Discordant helix stabilization for prevention of amyloid formation |
AU2002365077A1 (en) * | 2001-09-19 | 2003-06-30 | Massachusetts Institute Of Technology | Methods and products related to non-viral transfection |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) * | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
CA2428740A1 (en) * | 2002-05-20 | 2003-11-20 | Bayer Corporation | Automated method and reagent therefor for assaying body fluid samples such as cerebrospinal fluid (csf) |
US20050147584A1 (en) * | 2004-01-05 | 2005-07-07 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
US20050031652A1 (en) * | 2003-02-25 | 2005-02-10 | Allergan, Inc. | Compositions and methods comprising memantine and polyanionic polymers |
ATE479752T1 (en) * | 2003-03-07 | 2010-09-15 | Alnylam Pharmaceuticals Inc | THERAPEUTIC COMPOSITIONS |
US20070179100A1 (en) * | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
EP1625138A4 (en) | 2003-04-17 | 2010-06-23 | Alnylam Pharmaceuticals Inc | Protected monomers |
EP2664672A1 (en) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
EP2508608A1 (en) | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
SG124419A1 (en) * | 2005-02-03 | 2006-08-30 | Agency Science Tech & Res | Polycations capable of forming complexes with nucleic acids |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
US20110223665A1 (en) * | 2008-07-25 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND |
WO2010017329A1 (en) * | 2008-08-06 | 2010-02-11 | Rgo Biosciences Llc | Molecular entities for binding, stabilization and cellular delivery of charged molecules |
WO2010088282A1 (en) * | 2009-01-30 | 2010-08-05 | Rgo Biosciences Llc | Nucleic acid binding assays |
AU2010321533A1 (en) * | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US20110218156A1 (en) * | 2010-02-04 | 2011-09-08 | Alexander Chucholowski | Molecular entities for binding, stabilization and cellular delivery of negatively charged molecules |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
WO2012122313A2 (en) | 2011-03-08 | 2012-09-13 | Access Pharmaceuticals, Inc. | Targeted nanocarrier systems for delivery of actives across biological membranes |
KR101465365B1 (en) * | 2013-10-15 | 2014-11-25 | 성균관대학교산학협력단 | Lipid-supported polymeric functional particles and method thereof |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US20190177800A1 (en) * | 2017-12-08 | 2019-06-13 | 10X Genomics, Inc. | Methods and compositions for labeling cells |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
JP2021525086A (en) * | 2018-05-30 | 2021-09-24 | アクソーラボズ ゲーエムベーハー | Methods for Detecting Oligonucleotide Conjugates |
CN114874358B (en) * | 2022-04-11 | 2023-05-02 | 上海师范大学 | Synthesis method and application of polynuclear cerium nano material |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000596A1 (en) * | 1988-07-07 | 1990-01-25 | The Trustees Of The University Of Pennsylvania | Method of modulating virus-host cell interactions using carbohydrates and carbohydrate derivatives |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
JPH05170650A (en) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | Medicinal composition and its production |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
WO1994001448A1 (en) * | 1992-07-06 | 1994-01-20 | Pharmagenics, Inc. | Oligonucleotides modified with conjugate groups |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
US5457187A (en) * | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
-
1994
- 1994-11-17 US US08/341,522 patent/US5691316A/en not_active Expired - Lifetime
-
1995
- 1995-06-01 CA CA002191777A patent/CA2191777A1/en not_active Abandoned
- 1995-06-01 AT AT95922923T patent/ATE186647T1/en not_active IP Right Cessation
- 1995-06-01 DK DK95922923T patent/DK0762898T3/en active
- 1995-06-01 ES ES95922923T patent/ES2139904T3/en not_active Expired - Lifetime
- 1995-06-01 WO PCT/US1995/006916 patent/WO1995032739A1/en active IP Right Grant
- 1995-06-01 AU AU27643/95A patent/AU2764395A/en not_active Abandoned
- 1995-06-01 EP EP95922923A patent/EP0762898B1/en not_active Expired - Lifetime
- 1995-06-01 DE DE69513395T patent/DE69513395T2/en not_active Expired - Fee Related
- 1995-06-01 JP JP8501182A patent/JPH10501237A/en not_active Withdrawn
- 1995-06-01 CN CN95194366A patent/CN1158088A/en active Pending
- 1995-06-07 US US08/480,833 patent/US5605890A/en not_active Expired - Lifetime
- 1995-06-07 US US08/480,834 patent/US5616565A/en not_active Expired - Lifetime
-
2000
- 2000-01-13 GR GR20000400052T patent/GR3032355T3/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000596A1 (en) * | 1988-07-07 | 1990-01-25 | The Trustees Of The University Of Pennsylvania | Method of modulating virus-host cell interactions using carbohydrates and carbohydrate derivatives |
WO1991002040A1 (en) * | 1989-08-04 | 1991-02-21 | Kosak Kenneth M | Cyclodextrin labels for nucleic acid and biochemical analysis |
JPH05170650A (en) * | 1991-12-19 | 1993-07-09 | Sanyo Kokusaku Pulp Co Ltd | Medicinal composition and its production |
WO1993023570A1 (en) * | 1992-05-11 | 1993-11-25 | Pharmagenics, Inc. | Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety |
WO1994001448A1 (en) * | 1992-07-06 | 1994-01-20 | Pharmagenics, Inc. | Oligonucleotides modified with conjugate groups |
Non-Patent Citations (9)
Title |
---|
AGRAWAL, SUDHIR ET AL: "GEM 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS", ANTISENSE RES. DEV. 1992, VOL. 2, NO. 4, PAGES 261-6 * |
DATABASE DISSERTATION ABSTRACTS UNIVERSITY MICROFILMS INTERNATIONAL; DOUGHERTY, JOSEPH PAUL: "SYNTHESIS AND PROPERTIES OF 2',5'-LINKED DNA, AND SELECTIVE CLEAVAGE OF RNA WITH SYNTHETIC CATALYSTS" * |
DATABASE WPI Section Ch Week 9332, Derwent World Patents Index; Class B02, AN 93-252662 * |
DISSERTATION ABSTRACTS INTERNATIONAL. VOLUME: 56, NUMBER 3, SECTION: B, PAGE: 1420. ABSTRACT OF THESIS (PH.D.), 1995, COLUMBIA UNIVERSITY, 166 PAGES * |
HURAUX J.M. ET AL: "Prospects and current data in antiviral chemotherapy", REV. PNEUMOL. CLIN., 1989, VOL. 45, NO. 3, PAGE(S) 99-105, FRANCE * |
J.L. HOFFMAN ET AL.: "The interaction of cyclodextrins with nucleic acids. A study of secondary structure in three transfer ribonucleic acids", BIOCHEMISTRY, vol. 9, no. 18, pages 3542 - 3550 * |
PATENT ABSTRACTS OF JAPAN vol. 17, no. 577 (C - 1122) 9 July 1993 (1993-07-09) * |
UENO M ET AL: "Arranging quaternary structure of peptides by cyclodextrin-guest inclusion complex: Sequence-specific DNA binding by a peptide dimer with artificial dimerization module", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1993, VOL. 115, NO. 26, PAGE(S) 12575-12576 * |
ZHAO Q ET AL: "Use of cyclodextrin as carrier for oligonucleotides", KEYSTONE SYMPOSIUM ON DRUG DELIVERY: BARRIERS TO DRUG TRANSPORT AND THE DESIGN OF NOVEL THERAPEUTIC AGENTS, HILTON HEAD ISLAND, SOUTH CAROLINA, USA, JANUARY 7-13, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, 1995, SUPPL. 19A, PAGE(S) 176. * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997010005A3 (en) * | 1995-09-12 | 1997-06-26 | Hybridon Inc | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
WO1997010005A2 (en) * | 1995-09-12 | 1997-03-20 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US8277846B2 (en) | 2000-12-19 | 2012-10-02 | California Institute Of Technology | Complexing agents for compositions containing inclusion complexes |
US7807198B2 (en) | 2000-12-19 | 2010-10-05 | California Institute Of Technology | Compositions containing inclusion complexes |
US7968123B2 (en) | 2000-12-19 | 2011-06-28 | California Institute Of Technology | Complexing agents for compositions containing inclusion complexes |
US8092833B2 (en) | 2000-12-19 | 2012-01-10 | California Institute Of Technology | Compositions containing inclusion complexes |
US8404662B2 (en) | 2002-09-06 | 2013-03-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8518388B2 (en) | 2002-09-06 | 2013-08-27 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8314230B2 (en) | 2002-09-06 | 2012-11-20 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8680202B2 (en) | 2002-09-06 | 2014-03-25 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8389499B2 (en) | 2002-09-06 | 2013-03-05 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8399431B2 (en) | 2002-09-06 | 2013-03-19 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8252276B2 (en) | 2002-09-06 | 2012-08-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8475781B2 (en) | 2002-09-06 | 2013-07-02 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8609081B2 (en) | 2002-09-06 | 2013-12-17 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US9550860B2 (en) | 2002-09-06 | 2017-01-24 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580244B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580243B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8580242B2 (en) | 2002-09-06 | 2013-11-12 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8603454B2 (en) | 2002-09-06 | 2013-12-10 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US8357377B2 (en) | 2002-10-09 | 2013-01-22 | Suzie Hwang Pun | Cyclodextrin-based materials, compositions and uses related thereto |
US8497365B2 (en) | 2007-01-24 | 2013-07-30 | Mark E. Davis | Cyclodextrin-based polymers for therapeutics delivery |
US9610360B2 (en) | 2007-01-24 | 2017-04-04 | Ceruliean Pharma Inc. | Polymer drug conjugates with tether groups for controlled drug delivery |
WO2010066908A1 (en) * | 2008-12-12 | 2010-06-17 | Eurogentec S.A. | Use of cyclodextrins to improve the specificity, sensitivity and yield of nucleic acid amplification reactions |
US9260711B2 (en) | 2012-09-13 | 2016-02-16 | Ge Healthcare Uk Limited | Solid matrix for one step nucleic acid amplification |
US11464871B2 (en) | 2012-10-02 | 2022-10-11 | Novartis Ag | Methods and systems for polymer precipitation and generation of particles |
US10781175B2 (en) | 2016-07-15 | 2020-09-22 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
US11447451B2 (en) | 2016-07-15 | 2022-09-20 | Am Chemicals Llc | Solid supports and phosphoramidite building blocks for oligonucleotide conjugates |
Also Published As
Publication number | Publication date |
---|---|
CA2191777A1 (en) | 1995-12-07 |
CN1158088A (en) | 1997-08-27 |
EP0762898A1 (en) | 1997-03-19 |
ES2139904T3 (en) | 2000-02-16 |
US5616565A (en) | 1997-04-01 |
AU2764395A (en) | 1995-12-21 |
GR3032355T3 (en) | 2000-04-27 |
DE69513395T2 (en) | 2000-07-27 |
DK0762898T3 (en) | 2000-04-25 |
US5691316A (en) | 1997-11-25 |
US5605890A (en) | 1997-02-25 |
ATE186647T1 (en) | 1999-12-15 |
EP0762898B1 (en) | 1999-11-17 |
JPH10501237A (en) | 1998-02-03 |
DE69513395D1 (en) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0762898B1 (en) | Cyclodextrin cellular delivery system for oligonucleotides | |
ZHAO et al. | Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery | |
Dong et al. | Strategies, design, and chemistry in siRNA delivery systems | |
EP0664833B1 (en) | Therapeutic anti-hiv oligonucleotide and pharmaceutical | |
RU2558258C2 (en) | Sirna conjugate and method for producing it | |
CN103747805B (en) | For treating, delaying and/or preventing human genetic disease's such as type of steirert-Batten-Gibb syndrome 1(DM1)Compound | |
EP2691118B1 (en) | Perfluorinated compounds for the non-viral transfer of nucleic acids | |
WO2007040469A2 (en) | Chloroquine coupled compositions and methods for their synthesis | |
CN107849567A (en) | A kind of siRNA, the pharmaceutical composition containing the siRNA and conjugate and their application | |
EP2264167B1 (en) | Double-stranded lipid-modified rna having high rna interference effect | |
US20080051323A1 (en) | Chloroquine drug compositions and methods for their synthesis | |
WO1998002448A1 (en) | Conjugates of minor groove dna binders with antisense oligonucleotides | |
EP0537299A1 (en) | Oligonucleotide-transport agent disulfide conjugates | |
US20050153913A1 (en) | Nucleic acid carrier compositions and methods for their synthesis | |
Abdou et al. | Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence | |
Habus et al. | Synthesis, Hybridization Properties, Nuclease Stability, and Cellular Uptake of the Oligonucleotide-Amino-. beta.-cyclodextrins and Adamantane Conjugates | |
US20030166512A1 (en) | Protein carrier system for therapeutic oligonucleotides | |
US20060040879A1 (en) | Chloroquine coupled nucleic acids and methods for their synthesis | |
EP0850070B1 (en) | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response | |
CN114681619B (en) | Aptamer complex based on Biotin-SA and application thereof | |
Zhao et al. | Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs | |
EP4286416A1 (en) | Carrier for functional nucleic acid and protein introduction | |
WO1995020404A1 (en) | Triplex-forming paired-ion oligonucleotides and methods for preparing and using same | |
AU2003236659B2 (en) | Cooperative oligonucleotides | |
Hsu | In Vivo Studies of DNA Nanostructures and Synthesis of Long, Repetitive DNA Sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194366.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CN CZ DE DK EE FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2191777 Country of ref document: CA Ref document number: 1995922923 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 288420 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995922923 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995922923 Country of ref document: EP |